000			02099 a2200577 4500
005			20250518083412.0
264		0	_c20200311
008			202003s 0 0 eng d
022			_a2352-3026
024	7		_a10.1016/S2352-3026(19)30236-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aGisslinger, Heinz
245	0	0	_aRopeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. _h[electronic resource]
260			_bThe Lancet. Haematology _cMar 2020
300			_ae196-e208 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aEquivalence Trials as Topic
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aInterferon alpha-2 _xtherapeutic use
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolycythemia Vera _xdrug therapy
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aPrognosis
650	0	4	_aRecombinant Proteins _xtherapeutic use
700	1		_aKlade, Christoph
700	1		_aGeorgiev, Pencho
700	1		_aKrochmalczyk, Dorota
700	1		_aGercheva-Kyuchukova, Liana
700	1		_aEgyed, Miklos
700	1		_aRossiev, Viktor
700	1		_aDulicek, Petr
700	1		_aIlles, Arpad
700	1		_aPylypenko, Halyna
700	1		_aSivcheva, Lylia
700	1		_aMayer, Jiri
700	1		_aYablokova, Vera
700	1		_aKrejcy, Kurt
700	1		_aGrohmann-Izay, Barbara
700	1		_aHasselbalch, Hans C
700	1		_aKralovics, Robert
700	1		_aKiladjian, Jean-Jacques
773	0		_tThe Lancet. Haematology _gvol. 7 _gno. 3 _gp. e196-e208
856	4	0	_uhttps://doi.org/10.1016/S2352-3026(19)30236-4 _zAvailable from publisher's website
999			_c30592017 _d30592017